Volume 10 Supplement 1
A New Radiological Classification for Massive Pulmonary Embolism (SPECS)
© Chubsey et al. 2015
Published: 16 December 2015
Massive pulmonary embolism (PE) carries a mortality of 11% however current classifications do not identify those most at risk. Lack of direction prevents effective utilisation of options of treatment. We have undertaken this study to develop a radiological classification of massive PE that shows correlation with clinical outcome.
The study was conducted using the radiology database to identify all patients who had a CT pulmonary angiogram during the 12 months of 2014. A total of 1923 CTPAs were conducted, of which 210 were reported as large PE. These were examined, those with a segmental PE or poor quality imaging were excluded, leaving 154, 91 (59%) females in the study. The classification assessed location of clot (L) in major pulmonary arteries (scores 1, 2 and 4), the degree of occlusion (o) (score 1,2 and 3) and the impact on the right ventricle (RVR) (scores 1,2 and 3). Interventricular septum morphology (S) was also assessed (scores 1, 2, 3 and 4). Multipliers were used obtain the total score, [(L × O) × RVR] + S. Maximum score 64. This score was correlated with clinical outcome.
Average age of 69 years (range 20-98 years), with 13 deaths, 4 primarily from PE (group A), the remainder from causes other than PE (group B). Group A had a median score of 28.5 (IQR 16.5-33.7) compared with survivors, median score of 6 (IQR 3-15), p = 0.005. 2 patients with scores 14 and 24 respectively died following thrombolysis and interventional radiology. 1 patient with a score of 33 survived after surgical pulmonary embolectomy.
The results from this study demonstrate that the UHNM PE score is able to distinguish those patients with a massive PE that are life-threatening. We suggest the score requires further evaluation.
The UHNM PE Score, a new radiologic classification of massive PE that may be utilised in evaluating available therapies.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.